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Abstract
Over the past few decades, remarkable advancements in the understanding of the origin of low-back pain and lumbar spinal disorders have
been achieved. Spinal fusion is generally considered the “gold standard” in the treatment of low-back pain; however, fusion is also
associated with accelerated degeneration of adjacent levels. Spinal arthroplasty and dynamic stabilization technologies, as well as the
continuous improvement in diagnosis and surgical interventions, have opened a new era of treatment options. Recent advancements in
nonfusion technologies such as motion-preservation devices and posterior dynamic stabilization may change the gold standard. These
devices are designed with the intent to provide stabilization and eliminate pain while preserving motion of the functional spinal unit. The
adaption of nonfusion technologies by the surgical community and payers for the treatment of degenerative spinal conditions will depend
on the long-term clinical outcome of controlled randomized clinical studies. Although the development of nonfusion technology has just
started and the adoption is very slow, it may be considered a viable option for motion preservation in coming years. This review article
provides technical and surgical views from the past and from the present, as well as a glance at the future endeavors and challenges in
instrumentation development for lumbar spinal disorders.
© 2011 SAS - The International Society for the Advancement of Spine Surgery. Published by Elsevier Inc. All rights reserved.
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Implantable spinal devices have had humble origins.
Spinous process wires and Harrington rods represent the
birth of metallic fixation of the spine. Through countless
iterations of improved designs, current spinal fixation sys-
tems have revolutionized the surgeon’s ability to stabilize
the spine through both anterior and posterior approaches.
Despite origins in fixation, the most rapidly expanding cat-
egory of spinal devices is those concerned with motion
preservation. Interestingly, many of these new motion-pre-
serving designs, such as posterior dynamic devices, have
borrowed heavily from their rigid stabilization cousins in
their methods of implantation and anchoring.
With this most obvious of distinctions made, spinal de-
vices can be organized into 2 main types: (1) devices to
effect fusion and (2) nonfusion, motion-preserving devices.
Fusion devices are those that either directly or indirectly
enable bone healing across a previously mobile motion
segment. Some are intended to contain bone graft or an
osteogenic substance, such as interbody cages or so-called
vertebral body replacements. Others function to provide a
mode of immediate and rigid immobilization, such as pedi-
cle screws and anterior instrumentation systems, to correct
spinal deformity, enhance bony healing, decompress neural
elements, and/or allow for recovery. Indications can span
the full gamut of disorders of the human spine.
Nonfusion methods have been suggested as an alterna-
tive to fusion for a variety of spinal disorders, including
scoliosis, spinal stenosis, and discogenic low-back pain.
Their common goal is to treat the underlying pathology by
replacing proinflammatory tissues, restoring spinal align-
ment, and decompressing neural elements while preserving
functional movement rather than obliterating it. In doing so,
it is hoped that many of the problems associated with fusion
can be obviated, such as prolonged recuperation time, bone
graft donor-site morbidity, pseudarthrosis, and adjacent seg-
ment degeneration (ASD). Because their success does not
rely on the often-unreliable occurrence of bone healing,
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nonfusion techniques may also lead to quicker recovery
periods. Among the most popular indications for motion-
sparing technology has been the treatment of degenerative
disc disorders of the lumbar spine, which is the focus of this
report.
Categorizing current lumbar
motion-preserving devices
Motion-preserving devices can be categorized into 4
main types: (1) total disc replacement (TDR), (2) prosthetic
nucleus replacement, (3) posterior dynamic devices, and (4)
facet replacement. Defining these different types of devices
is a worthwhile exercise.
TDRs necessitate nearly complete removal of the disc.
The implant contains endplate portions, usually constructed
of a metallic composite, that are fixed to the vertebral
endplates. The articulating portion of the device is inter-
posed between the endplates and can be composed of var-
ious materials.
Contrasting TDR, prosthetic nucleus replacements ne-
cessitate evacuation of only the nucleus pulposus through an
annulotomy. Otherwise, the annulus remains largely intact.
The implant is usually a deformable material that is inserted
into the disc space with or without a fixation method.
Posterior dynamic devices come in many forms. Dy-
namic, or so-called soft, stabilization and semirigid are both
typically pedicle screw based. The screws are connected by
a flexible longitudinal member. Currently available devices
vary from articulating ball joints to longitudinal Silastic
rods. Although they may be considered a separate category,
interspinous process devices may also be considered poste-
rior dynamic stabilization devices. These devices consist of
an implant that is interposed between the spinous processes.
Some are held in place by geometry alone, whereas others
rely on supplemental tethering fixation.
There is some conceptual overlap between facet replace-
ment and posterior dynamic stabilization. For the purposes
of this article, facet replacement will be defined as those
devices that replace and simulate the function of either the
entire facet joint or its articulating surfaces. Although they
may be marketed as facet replacements, devices that include
a continuous connecting member between vertebral levels
should more appropriately be termed dynamic stabilization
devices.
Total Disc Replacement
The past:
Initial concepts for TDRs arose more than 30 years ago.
Because the intervertebral disc is a complex anatomic and
functional structure, an efficient and reliable artificial disc is
expected to reproduce the motion as well as bear the loads.1
Kostuik2 proposed a disc design with metal endplates held
apart by a spring. Lee and Goel3 have documented 25 years
of work on a TDR that uses an elastomeric material between
the endplates, which has only recently begun investigational
clinical trials. In 1978 Steffee suggested the use of a ball-
and-socket joint that was cemented into the vertebral bodies
with a posteriorly located center of rotation. Steffee’s
AcroFlex disc (AcroMed Corp, Cleveland, OH), which had
a closed envelope to contain wear debris, was quickly aban-
doned after only a handful of clinical implantations. A
myriad of other design patents have been submitted over the
past 20 years that have never seen clinical fruition.4
The present:
At the time of this writing, there are 2 TDRs approved
for use by the Food and Drug Administration (FDA): In-
Motion/Charité III from DePuy Spine, Raynham, Massa-
chusetts, and ProDisc from Synthes, West Chester, Penn-
sylvania (Fig. 1). Within a discussion of “the present”
designs, however, the prerelease history of these devices is
important to understand.
In the early 1980s, Schellnack and Büttner-Janz designed
the initial Charité disc replacement.5–7 They relied on con-
cepts derived from total hip and knee prostheses that, for the
most part, used polyethylene-on-metal articulating surfaces.
Like the current version, the device had a freely mobile
polyethylene core (Ultra High Molecular Weight Polyeth-
lene [UHMWPe]) that has convex surfaces, which articulate
with concave metallic endplates (Charité I and II used
stainless steel whereas Charité III and InMotion use cobalt-
chromium-molybdenum (CoCrMo) with titanium calcium
phosphate coating). The small size of the Charité I implant
led to a high frequency of subsidence. The Charité II at-
tempted to remedy this problem by including thin lateral
Fig. 1. Lumbar disc replacement: a, InMotion; b, Charité III; and c, ProDisc II.
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wings to increase the surface area. Unfortunately, these
wings developed early fractures. The third version of
Charité was developed in 1987. It featured a substantially
broadened, flat endplate design that minimized endplate
subsidence and fractures that were observed with the first
and second generations. In 2007 the InMotion disc replace-
ment was released to facilitate the insertion of the Charité
III. The new InMotion design retains the essential charac-
teristics of the Charité III design with only the modifications
involving the teeth orientation and the addition of a central
rail portion allowing the prosthesis to glide onto a ramp
inserter.
The endplate of the InMotion and Charité III is manu-
factured from a CoCrMo alloy. This material has been
found to result in less polyethylene wear debris than tita-
nium or stainless steel in total hip and knee replacements.
To maximize osseous integration, the endplates have a po-
rous coating made of titanium and a layer of calcium phos-
phate. The design improvements of the current model ap-
pear to successfully address issues of implant subsidence
and fatigue fracture. Analyses of revision cases have shown
acceptable levels of polyethylene debris and substantial
percentages of bony ingrowth.8,9 The design of the core is
intended to prevent core migration; reports of device mi-
gration could be due to excessive resection of the annular
ring and positioning the device in hyperextension. Compli-
cations with the Charité III from Europe have much to do
with (1) the implant endplate sizes offered at that time and
(2) the lack of understanding of the best clinical indications
and refined surgical techniques and instruments.10
In comparison to most other TDR designs, the distin-
guishing design feature of the Charité III is a sliding, freely
mobile polyethylene core. With this design, the instanta-
neous axis of rotation is permitted to translate anterior and
posterior to the midpoint of the disc during extension and
flexion, respectively. Cunningham11 showed that the motion
of the Charité III disc closely parallels normal motion in a
cadaveric model. He found that the disc restored motion to
that of the intact segment in flexion-extension and lateral
bending; however, axial rotation exceeded normal limits. In
addition, he found that the Charité III preserved the seg-
mental kinematics and centroid of intervertebral motion at
the operative and adjacent spinal levels compared with
conventional methods of stabilization.
Early and medium-term clinical results with the Charité
III for the treatment of low-back pain from degenerative
disc disease (DDD) have been encouraging.12 Review of
these results led to its approval as the first TDR for general
use in the United States by the FDA, in 2004, as an alter-
native to lumbar fusion. Though not statistically different,
results in the Charité patients tended to be better in this
highly select group. Complication rates were similar in the
TDR and fusion groups. Long-term results are available
from Europe. With a minimum follow-up of 10 years, Le-
maire et al13 and David14 reported good or excellent clinical
outcomes in 90% of patients. Furthermore, they showed a
mean of 10.3° of motion in flexion-extension at follow-up.
Clinical failures of the Charité III have been reported re-
cently.10,15 Most of these failures could be linked to the
application of the artificial disc in what is considered a
contraindication in the FDA investigational device exemp-
tion (IDE) study.
The history of the ProDisc device has followed a similar
path. In the late 1980s, Marnay developed the initial proto-
types of the ProDisc. After the initial introduction of the
ProDisc I, the ProDisc II was developed. In contrast to the
Charité, the current ProDisc implant relies on a single ar-
ticulating interface between the superior metallic endplate
and the superior surface of the polyethylene core. It can be
considered a semiconstrained device; the polyethylene core
(bearing surface) is fixed to the inferior endplate but not to
the superior endplate. Fixation of the endplates is enhanced
by a single midline sagittal keel and 2 small spikes, in
contrast to the 6 small teeth of the Charité III.
There are biomechanical differences between the InMo-
tion/Charité III and the ProDisc II. By design, with the use
of a fixed center of rotation, there is an obligatory amount of
sagittal translation that is produced on the ProDisc during
flexion and extension. This is a product of a rotational axis
that lies within the anterosuperior aspect of the lower ver-
tebral body. It is thought that this could produce abnormal
forces within the facet joints and anteroposterior dimen-
sional changes of the neuroforamina during sagittal motion.
Short- and long-term follow-up studies have shown good
clinical results with the ProDisc II.16–18 Radiographic anal-
ysis has shown at least 2° of sagittal motion in 66% of
prostheses after a mean of 8.7 years; the mean range of
motion of all prostheses was 3.8°. The prevention of ASD
has been one of the primary impetuses for TDR develop-
ment, as ASD was reported in 24% of fusion cases, although
no patients required surgical intervention. Because its pre-
vention has been one of the primary impetuses for TDR
development, ASD was reported in 24% of cases, although
no patients required surgical intervention.19 As with the
Charité III, complications have been reported. The size of
the endplate keel has been reduced after reports of vertebral
body–splitting fractures during insertion. The ProDisc was
approved by the FDA in 2006.
There are a number of other lumbar TDRs that have been
under investigation and are emerging onto the market, such
as the Maverick (Medtronic Sofamor Danek, Memphis,
Tennessee), FlexiCore (Stryker, Allendale, New Jersey),
Kineflex (SpinalMotion, Mountain View, California), Mo-
bidisc (LDR, Troyes, France), XL TDR (NuVasive, San
Diego, California), Freedom Lumbar Disc (Axiomed Spine,
Cleveland, Ohio), Activ-L (Aesculap B. Braun, Tuttlingen,
Germany), and Triumph (Globus Medical, Audubon, Penn-
sylvania) (Fig. 2). This device list is unlikely exhaustive but
aims to offer an overview of the current technologies avail-
able on the market today. Although they all have some
unique features, their general design concept is that of a
semiconstrained TDR with articulating surfaces. Clinical
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results appear to be similar to those for the Charité and
ProDisc20; however, a thorough comparison between im-
plant designs and associated clinical outcomes has yet to be
published.
The Maverick consists of 2 metallic CoCrMo end-
plates that directly create a ball-and-socket system with
the rationale to minimize wear, a posterior center of
rotation to match that of the disc segment aimed at
unloading the facet joint, and hydroxyapatite (HA) coat-
ing on the bone-implant interface to maximize early
fixation with bony ingrowth. CE mark was obtained in
2001, and the prosthesis has been in clinical use since
2002. The first FDA clinical study started in 2003 and
closed in 2010 with positive results. FDA approval is still
pending at this stage, and a second US study started in
2009 with estimated study completion in 2013.
The FlexiCore disc is a 2-piece constrained metal-on-
metal device designed as a ball-and-socket joint where no
translation of the endplate is allowed. The clinical IDE
enrollment is completed. Three-year preliminary results are
being presented as encouraging, but full study data are still
required to confirm these.
The Kineflex is a 3-piece metal-on-metal design (2
keeled CoCrMo endplates and 1 semiconstrained, fully ar-
ticulating CoCrMo core) that aims to provide a freedom of
movement with translational stop. It has been used since
2002 outside the United States. An FDA IDE study com-
menced in 2005 with a comparison to the Charité TDR and
closed in 2006, with follow-up on the over 500 patients up
to 3 years at this stage. FDA approval has not been granted
yet.
The Mobidisc is a 3-piece design with 2 metallic
endplates with a modular keel and a polyethylene core
with geometries allowing an on-constraint prosthesis
with controlled mobility in all axes. The device was
released in 2003. It is currently not available in the
United States.
Other devices, such as the XL TDR, have a metallic
design that is implanted from the patient’s side, with a
similar approach to Extreme Lateral Interbody Fusion
Fig. 2. Lumbar disc replacement: a, Maverick; b, FlexiCore; c, Kineflex; d, Mobidisc; e, XL TDR; f, Freedom; g, Activ-L; and h, Triumph.
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(XLIF) cages. An FDA trial started in 2009 with an esti-
mated primary completion date in 2012.
The Freedom Lumbar Disc is made of a silicone poly-
carbonate-urethane polymer core that is bonded between the
2 metal endplates to allow controlled motion and enable
shock-absorption capability. The device has been used in
Europe, and FDA trials started in 2008 with an estimated
primary completion date in 2012.
The Activ-L prosthesis consists of a polyethylene core
that has controlled anterior-posterior translation capability
between 2 metallic endplates that can be inserted from an
anterior, anterior-lateral, or lateral approach. An FDA trial
started in 2007, enrollment was completed and currently it
is in the final stages of data collection and submission.
The Triumph consists of 2 metallic endplates with a
geometry allowing it to be inserted through a posterolateral
approach. An IDE study started in 2007; it is still ongoing
but no longer recruiting.
At the time of this writing, there are also other devices
either under clinical investigation outside the United States
or available internationally, such as the Dynardi Artificial
Lumbar Disc (Zimmer, Warsaw, Indiana) with 2 metallic
endplates on a polyethylene-core design, Lumbar Motion
Preservation (LMP; Vertebron, Stratford, Connecticut),
CadiscL (Ranier Technology, Cambridge, United Kingdom)
with a polyurethane-polycarbonate graduated modulus
monobloc design, Physio-L (Nexgen Spine, Whippany,
New Jersey) with a titanium porous endplate directly linked
onto a polycarbonate-polyurethane core, Total Spinal Mo-
tion Segment System (TSMS; Disc Motion Technologies,
Boca Raton, Florida) with a metallic rod with a built-in
damper, eDisc (Theken Disc, Akron, Ohio) with a polymer
bounded between metallic endplates with additional micro-
electronics allowing activity monitoring, Welldisc (Eden
Spine, Lake Mary, Florida) with a metallic endplate and poly-
ethylene core, La Jolla (Seaspine, Vista, California), and M6L
(Spinal Kinetics, Sunnyvale, California) with a shock-absorb-
ing core encapsulated within a polymer sheath mimicking the
annulus fibrosus bound into metallic endplates.
The future:
Notwithstanding material and specific design differ-
ences, the motion-producing mechanism of most TDRs is
essentially a ball joint. Though much more sophisticated,
this is quite analogous to Fernström metal balls. Other
features such as elastic shock-absorption properties are not
approximated with any of these designs. LeHuec et al21
have shown that there is no difference in the shock absorp-
tion provided by a hard polymer core or a metal-to-metal
device. However, this will likely be a focus of future de-
signs. There are a number of ways that axial compressibility
(shock absorption) can be achieved in a TDR. In his early
patents, Kostuik2 described the use of a spring. This is not
likely to be adopted, because there are a finite number of
cycles before which a metallic spring will fail. Other inves-
tigators have proposed the use of a rubbery-type substance.
Limitations in material design led to failure of the AcroFlex
disc in the 1990s. Most recently, Lee and Goel3 have finally
introduced their TDR design that uses an elastomeric core
material that is affixed to the metallic implants by a propri-
etary process. Interestingly, such a design has inherent lim-
its to range of motion; it has been proposed that the material
and structural properties of the elastomeric material have
been optimized to closely approximate those of the intact
disc. However, creep deformations and hysteresis properties
of elastomeric materials may be limiting factors in this
application.
Future advancement of lumbar TDR may have little to do
with the design of the device. Because difficult revision sur-
gery may be a factor limiting general acceptance of TDR,
methods of scar prevention between the spine and the neigh-
boring retroperitoneal structures have been sought. This may
be in the form of biologically inert or active membranes.
Nucleus Replacement
The past:
In considering Fernström balls, one might be hard-
pressed to describe them as a TDR according to the defini-
tions described previously. More accurately, they may be
described as a nucleus replacement. As such, Fernström
balls are the predecessors of modern nucleus replacements.
A subset of nucleus replacement is nucleus augmentation,
which may be defined as those substances that are injected
into the disc space and cured in situ. This seemingly novel
idea has its roots in Nachemson’s attempt to augment a
degenerated disc with injected silicone.
The present:
Although there are no nucleus replacements or augmen-
tation devices that are currently approved for use in the
United States, there are a number that are under clinical
investigation.
Ray22 designed the original Prosthetic Disc Nucleus
(PDN; Raymedica, Minneapolis, Minnesota) as well as sev-
eral subsequent modifications (Fig. 3). The PDN is intended
to be a treatment for discogenic low-back pain from DDD or
after discectomy. In distinction to TDRs, the PDN is placed
through a posterior laminectomy and standard discectomy/
annulotomy approach. The PDN’s essential component is a
hydrophilic gel pillow that absorbs water and expands once
Fig. 3. Nucleus pulposus supports: a, PDN; and b, DASCOR.
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implanted. The gel pillow is contained by a polyethylene
mesh “pillow cover” to prevent overexpansion. The initial
design that was clinically released in 1996 included 2 pil-
lows placed transversely within the disc space. Current
versions call for right and left pillows to be placed in an
anteroposterior orientation.
One of the major design challenges of any nucleus re-
placement or augmentation method is to prevent expulsion
of the device from the disc space. Migration and subsidence
with the first-generation PDN were reported. Thus subse-
quent versions, such as PDN-SOLO and PDN-SOLO XL,
include a suture fixation method. In addition, the insertion
approach has been changed. Using a direct lateral approach
avoids an open annulotomy within the epidural space. Early
clinical results have been encouraging. Pain relief has been
reported with the PDN at 6 months and 1 year of follow-
up.23,24 However, migrations have continued to occur25
with disc herniations. Raymedica has reported that over
4,000 patients worldwide have received either the PDN or a
PDN-SOLO implant. Only recently has the PDN-SOLO
device been implanted in the United States as part of a
nonrandomized, prospective clinical trial. In 2006 Ray-
medica released the Hydraflex system, with a more anatom-
ically profiled implant, softer core, larger footprint, quicker
absorption capability, and specially dedicated instrumenta-
tion to facilitate repeatable meticulous implantation aimed
at reducing the extrusion complication rate.
The DASCOR Disc Arthroplasty System (Disc Dynam-
ics, Eden Prairie, Minnesota), which is another PDN device,
uses an in situ, curable polymer and is indicated for treating
patients with chronic low-back pain caused by DDD. This
system has been CE marked in Europe, and the clinical
investigation in the United States stopped enrollment in
early 2007. The DASCOR device consists of a 2-part cur-
able polyurethane and an expandable polyurethane balloon,
which is inserted into the disc nucleus space after the nu-
cleus has been removed.26 The balloon is then injected with
the flowable polymer, which creates a complete patient-
specific implant that conforms to the shape and size of the
disc space. The flowable polymer cures, creating a firm but
pliable implant. Disc Dynamics reported that clinical study
results using the DASCOR Disc Arthroplasty System have
shown that most patients have had improvement in pain and
function.27 Because no 2 patients recover at the same rate,
no guarantees can be given on the rate or degree of pain
relief each individual can expect. Disc Dynamics started to
liquidate its assets in 2009, and currently, support on the
IDE study sought for its DASCOR device remains unclear.
The NeuDisc spinal nucleus implant (Replication Med-
ical, Cranbury, New Jersey) is designed to replace the native
nucleus pulposus, restore function to the disc, and slow or
reverse the degenerative process. The NeuDisc is intended
to be implanted through standard minimally invasive surgi-
cal procedures. The device is a small, coin-sized implant
composed of 2 grades of a modified hydrolyzed poly-acry-
lonitrile polymer (Aquacryl, Replication Medical, Cran-
bury, New Jersey). The Aquacryl polymer is reinforced by
a Dacron mesh. It is inserted in a dehydrated state, which
allows the implant to be placed via minimally invasive
methods. Once inserted, it absorbs up to 90% of its weight
in water in an anisotropic fashion to restore disc height and
improve compressive axial load resistance.28 This hydrogel
material device has the advantage of allowing fluid com-
munication and potential nutrient flow between the vertebral
bodies, similar to the native nucleus.
The NUBAC disc arthroplasty system (Invibio, Green-
ville, North Carolina/Pioneer, Driebergen, The Netherlands)
has been designed to restore and maintain load-sharing
capabilities of the implanted disc. It is a polyether ether
ketone (PEEK)–on–PEEK system with articulating surfaces
and an endplate that is slightly concave. PEEK has an elastic
modulus similar to underlying bone and magnetic resonance
imaging compatibility. Implantation is less invasive with
this nucleotomy procedure. The relatively small bearing
implant system is placed in the center of the endplate and is
expected to resist expulsion well. A clinical trial study was
initiated in the United States in 2009, and the most recent
update, from 2010, indicated that the study was still ongoing
but no longer recruiting patients.
The NuCore Injectable Nucleus (Spine Wave, Shelton,
Connecticut) is designed to provide patients and surgeons
with a minimally invasive surgical alternative for treating
the early stages of DDD and as an adjunct to microdiscec-
tomy (Fig. 4). The NuCore Injectable Nucleus is an inject-
able, 100% synthetic recombinant protein hydrogel de-
signed to mimic the natural nucleus and restore the spine’s
natural biomechanics. This device is designed with the
premise to restore the biomechanics of the disc after micro-
Fig. 4. Nucleus pulposus alternatives: a, NuCore; b, NeuDisc; c, NUBAC; and d, PDN.
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discectomy and reduce accelerated disc degeneration. Bio-
mechanically, the hypothesis regarding NuCore is that it
will augment the remaining nucleus material and restore the
spine’s natural biomechanics.
TranS1 (Wilmington, North Carolina) has released the
Percutaneous Nucleus Replacement (PNR). It consists of a
titanium screw system anchoring itself onto the superior and
inferior vertebrae, with a central membrane that is filled
with curable material and acts as the nucleus. It is inserted
in a caudal-rostral manner anterior to the sacrum axially
through the vertebra to replace the damaged disc and restore
the natural motion while also preserving the integrity of the
annulus fibrosus and ligaments so as to reduce the risk of
implant migration. Because of the approach, the system is
limited to L5-S1. It has been in limited use since 2008, and
its clinical performance has yet to be evaluated.
At the time of this writing, there are also other systems
available such the BioDisc (CryoLife, Atlanta, Georgia),
DiscCell (Gentis, Wayne, Pennsylvania), and GelStix (Rep-
lication Medical).
The complications of nucleus replacement devices typi-
cally includes: 1) implant expulsion, especially with those
devices without retaining means, because the annulus fibro-
sus is weakened to allow insertion; 2) subsidence, especially
in stiff devices because of high stress created in the center
of the endplate; 3) endplate remodeling with loss of disc
height; and 4) poor disc kinematics resulting in neural
impingement and facet degeneration or fracture.
The future:
Assuming nucleus replacement and augmentation de-
vices will be approved for use in the United States, a future
challenge will be to distinguish which patients are ideal
candidates. At this time, it is unclear who would benefit
from a TDR versus a nucleus replacement.22 Some inves-
tigators have considered advanced disc space collapse (5
mm of residual disc height), endplate defects, and obesity
(body mass index 30) to be contraindications to nucleus
replacement. Despite these mechanical considerations, more
fundamental questions regarding low-back pain generators
remain unanswered.
New generations of injectable polymeric nucleus devices
that can cure in situ are in the beginning phases of devel-
opment. Hydrogel materials intended to restore the disc
height by supplementing the dehydrated and degenerated
nucleus pulposus are also in development. The goals of
these devices are to restore physiologic intervertebral liga-
mentous stress and annular tension to re-establish spinal
kinematics. One of the impetuses for developing injectable
devices is to lower the chance for extrusion, because they
are implanted through a smaller needle-stick annulotomy. In
addition, insertion is potentially less invasive than with
nucleus replacement. Other challenges arise, though, such
as the ability to maintain disc space height long-term,
achieving adhesion to the host tissue, and creep. As a
minimally invasive procedure, its future role may be to
delay or mitigate the need for open surgical treatment of
discogenic low-back pain.
There are a number of devices and drugs that are cur-
rently in development. Intradiscal rhGDF-5 is a new drug
being developed for the treatment of early DDD. The active
pharmaceutical ingredient is recombinant human growth
and differentiation factor 5 (rhGDF-5). Growth and differ-
entiation factor 5 is a member of the transforming growth
factor  superfamily and the bone morphogenetic protein
subfamily and is known to influence the growth and differ-
entiation of various tissues. Preclinical studies suggest that
intradiscal rhGDF-5 is safe in the intended route of admin-
istration. Moreover, preclinical studies in animal models of
disc degeneration have shown the ability of rhGDF-5 to
reverse the degenerative changes as evidenced by an in-
crease in disc height and hydration, as indicated by T2-
weighted magnetic resonance imaging, as well as reduce the
cytokine expression in degenerative animal discs. Currently,
rhGDF-5 pilot clinical studies are being conducted to prove
the safety and efficacy before pivotal studies.
Another area of future development will be techniques
for annular repair or reconstruction. Sealing the annulus
after nucleus replacement might have benefits in diminish-
ing the chance for extrusion. The key types of surgical
sealants are fibrin sealants, synthetic agents, collagen-based
compounds, and tissue adhesive glues such as hydrogel.
Fibrin sealants are popular because of their safety, low risk
for infection, and promotion of natural tissue healing. Such
barriers have shown decreased scar formation in animal
models.29
Furthermore, annular reconstruction may an attractive
method of decreasing the rate of reherniation after standard
discectomy. However, the annular ring is subjected to pres-
sures as high as 3.5 MPa, so annular repair must be robust
enough to withstand these high pressures and prevent disc
reherniation. Other theoretic benefits have also been pro-
posed, such as containment of water and neural inflamma-
tory factors within the disc, which might reverse or arrest
disc degeneration and lessen radiculopathy, respectively.
Posterior dynamic stabilization devices
Posterior nonfusion stabilization of the lumbar spine had
been infrequently practiced before the last decade.30,31
Early attempts ranged from tethering artificial ligaments to
interspinous distraction devices. Early failures prevented
further interest until recently, although posterior dynamic
stabilization has become one of the most rapidly evolving
fields in spinal surgery. This new category of thoracolumbar
spinal surgery focuses on the concept of maintaining or
restoring intervertebral motion in a controlled fashion,
whether by restricting spinal motion or by dampening the
kinetic energy involved in motion. The goal of these im-
plantable devices is to restore the behavior of the spinal
column and potentially prevent ASD.32
With greater focus on motion-preservation alternatives,
interest in posterior dynamic stabilization has grown. Var-
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ious devices have sought a wide array of indications, in-
cluding accelerated fusion, treatment of discogenic low-
back pain, treatment of facet pain, treatment of spinal
stenosis, controlling motion in degenerative spondylolisthe-
sis or iatrogenic destabilized spine, treatment of neurogenic
claudication, and prevention of ASD at the time of fusion.
Interspinous devices:
The past: What is old is new; more importantly, what is
new is old. Although the surge of interspinous devices to the
spine market would have the casual observer convinced that
they are the product of a recent brainstorm, it is not the case.
The notion of an interspinous device to produce segmental
posterior distraction was first introduced in the 1960s by Dr
Fred Knowles. Better known for his hip pin design, he
reported limited success with his spinal device because of
subsidence and displacement. He would not have seen the
reincarnation of his ideas in the form of an X-stop (Kyphon,
Sunnyvale, California) for 3 decades.
The present: Several types of interspinous devices have
been developed. At the time of this writing, X-stop is the
only approved device. Others, such as the Wallis system
(Abbott Spine, Austin, TX; acquired in 2008 by Zimmer),
Minns silicone distraction device, CoFlex system (Paradigm
Spine LLC, New York, New York), and DIAM (Medtronic
Sofamor Danek) are under clinical investigation with the
intent to seek FDA approval (Fig. 5). They all work to limit
spinal extension. These interspinous spacers may be helpful
when more conservative (nonoperative) care does not im-
prove symptoms. They can be used in elderly adults who are
not well enough to undergo surgery; indeed, most recent
devices can be inserted without tissue or bone removal and
without the need for general anesthesia. The indications for
these devices remain to be defined. Manufacturers’ reported
indications include DDD, ASD, facet syndrome, spinal ste-
nosis, and nontraumatic instability. Interestingly, some de-
vices, such as the CoFlex, have sought approval as fusion
devices because they are constructed of allograft bone.
All these devices hold the spine in a position of slight
flexion to decompress the spinal cord or spinal nerve roots.
The spine can still rotate or bend to the side when the spacer
is in place. All interspinous spacers can be categorized into
2 groups: static spacers allow constant extension, whereas
dynamic spacers are compressible by use of an elastomeric
material.
The X-stop is made of titanium and PEEK components,
with side wings encapsulating the lateral sides of the spi-
nous processes to reduce the risk of implant migration. FDA
Fig. 5. Interspinous spacers: a, Wallis system; b, DIAM system; c, X-stop; and d, CoFlex.
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approval was obtained in 2005 after a 2-year clinical study.
The device is approved for use in patients aged 50 years or
older with lower-extremity neurogenic pain from lumbar
spinal stenosis and can be inserted under local anesthesia.
The ligaments around the spine are saved from being cut.
The device slips through a slit made in the ligament. In the
pilot study, inclusion criteria were mild or moderate symp-
toms that were relieved by flexion and the ability to walk at
least 50 ft. Exclusion criteria were a fixed motor deficit or
spondylolisthesis of grade II or higher.33,34 Clinical studies
by Anderson et al35 showed overall clinical success in
63.4% of the study group but in only 12.9% of the control
group at 2-year follow-up. Clinical failure includes lami-
nectomy and fusion with no evidence of any nerve injuries
or neurologic deterioration. At present, 30,000 patients have
been treated with X-stop.
The Wallis system was first released clinically in Europe in
1987 under the form of a titanium spacer design that has since
been replaced by a plastic-like polymer material (PEEK) that is
secured between the spinous processes with a woven polymer
flat band so as to reduce implant migration risk and constraint
motion to prevent extreme movements. FDA clinical trials
started in 2007 and are currently at the stage of final data
collection for primary outcome measurement.
The DIAM system is made of a silicon H-shaped spacer
encased within a polyester jacket that is secured (after
removal of the interspinous ligament) with a cord similar to
the Wallis system’s. The first clinical case was performed in
1997 in France, and 25,000 patients have been treated out-
side the United States since then. FDA clinical trials have
also started, such as the study relating to the effectiveness of
DIAM versus decompression versus posterolateral fusion
that started in 2008 and closed in December 2010 with final
data collection for primary outcome measurement or the
study relating to the effectiveness of DIAM versus conser-
vative care that started in 2007 and has a primary comple-
tion date estimated for 2013.
The CoFlex is based on the interspinous-U design from
Fixano (Péronnas, France) that was clinically used from
1995 onward. It is made in its classic form as a titanium
U-shaped metal design that is maintained between spinous
processes with side wings, so as to control movement while
allowing motion, being marketed as a nonfusion device. The
CoFlex-F device has also been released. On the basis of the
CoFlex design, bolts are added through the holes of the
wings to rigidly secure those onto the spinous processes; it
is indicated for fusion, as an alternative to pedicle screw
fixation as an adjunct to interbody fusion. The IDE study
started in 2007 and is still recruiting patients.
The future: There are many interspinous distraction devices
planned for future study. Some are compressible, such as
the CoFlex, DIAM, or Minns devices,36 whereas others are
noncompressible. Fixation techniques also vary. Although
the rationale for their use in the treatment of spinal stenosis
is clear, the role in the treatment of DDD remains to be
defined. One proposed mechanism of action is unloading of
the posterior annulus by distraction. Interspinous devices
with shock absorption and postoperative adjustability may
present the future of these devices.
In recent years multiple companies have offered various
devices, such as NuVasive with ExtendSure; Biomech’s
(Taipei, Taiwan) Promise and Rocker designs, made of
PEEK and mobile core and articulated design, respectively;
Cousin Biotech (Wervicq-Sud, France) with Biolig silicon
encapsulated in woven synthetics; Alphatec (Carlsbad, Cal-
ifornia) with the HeliFix screw-type PEEK space design;
Vertiflex (San Clemente, California) with the Superion im-
plant whose deployable wings aim at less invasive insertion
(IDE study started 2008); Synthes with the In-Space system
with minimal insertion (IDE study also started in 2008);
Medtronic’s Aperius PercLID implant (IDE study started in
2009), Orthofix (Bussolengo, Italy) with InSWing; Pioneer
with BacJac; Maxx Spine (Bad Schwalbach, Germany) with
I-MAXX; Sintea Plustek (Assago, Italy) with Viking; Glo-
bus Medical with Flexus; and Privelop (Neunkirchen-Seel-
scheid, Germany) with Spinos (Fig. 6).
The typical complications of interspinous devices in-
clude spinous process fracture, especially with stiff design;
novel radiculopathy, especially with devices with limited
motion-constraining ability; and returning or increased pain
around the implant area. Implant dislodgement is also a
potential complication, particularly in those designs with
limited fixation means.
Posterior dynamic, or “soft,” stabilization
The past: The Graf ligament is one of the earliest attempts
at posterior dynamic stabilization (PDS) (Fig. 7). Developed
in France by Dr H. Graf, it included artificial ligaments that
were fixed to pedicle screw anchors. The ligaments were
tensioned to provide stability. Clinical reports of its use
have been published with mixed results.37–39 Some of the
variation may be from variability of indications. However,
device-related complications are not uncommon. Over-ten-
sioning of the ligament has led to foraminal stenosis and
new-onset radiculopathy. Pedicle screw loosening has also
been reported.
The present: Current PDS systems purport the ability to
allow controlled motion in such a way as to achieve more
normal movement of the spine. The Dynesys system (Zim-
mer Spine, Warsaw, Indiana) was developed by Gilles
Dubois in 1994. In its present form, the system consists of
titanium alloy (Protasul 100) pedicle screws and a stabiliz-
ing spacer made of polyester (Sulene-PET) cords and a
polycarbonate-urethane (Sulene-PCU) tube. The spacer fits
between and is fixed to the pedicle screw heads. In exten-
sion, the tube resists compression; in flexion, the polyester
cord resists tension. The device has been used in Europe for
a variety of indications with mixed results.40,41
The IsoBar (Scient’X, Beaurains, France) and AccuFlex
(Globus Medical) rod systems are other examples of PDS
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Fig. 6. Other interspinous spacer alternatives: a, Promise; b, Rocker; c, Biolig; d, HeliFix; e, Superion; f, In-Space; g, Aperius; h, InSWing; i, BacJac; j,
I-MAXX; k, Viking; l, Flexus; m, Spinos; and n, Wellex (Eden Spine).
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Fig. 7. Posterior dynamic stabilization: a, Graf system; b, Dynesys; c, IsoBar; d, AccuFlex; e, Stabilimax; f, Percudyn; and g, Transition.
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systems. These devices’ rods rely on a flexible section of
rod to provide a low stiffness connection between screws.
They provide less rigidity, permitting load sharing with the
anterior column. Both systems received FDA clearance as
fusion devices. The IsoBar relies on a damper system
(stacked titanium disc-shaped elements) that allow micro-
motion of the rod; it has been used since 1993 in Europe
and became available in 2003 in the United States, al-
though the FDA has issued warning letters in 2010 and
2011 to question the postmarket surveillance plan in
place. The manufacturer is currently indicating that the
product promotes stimulated and improved fusion. The
AccuFlex semirigid system is created by a helical cut
within a standard metallic rod. There has been concern
about the issue of ingrowth within the spiral that might
prevent proper functioning of the device throughout time.
Globus Medical currently also offers the Transition sys-
tem claiming to optimize load sharing while ensuring
transitional stabilization, with a design appearing to be
similar to that of Dynesys. In 2010 it was announced that
2,000 patients had already been treated with this device.
To date, however, there are no peer-reviewed clinical
articles on the use of any of the previously listed devices
as nonfusion dynamic stabilization systems.
The Stabilimax (formerly known as the M-Brace; Ap-
plied Spine Technologies, New Haven, Connecticut), in-
vented by Manohar Panjabi, has been specifically de-
signed as a treatment for DDD and chronic low-back
pain. This implant is unique in that relies on dynamiza-
tion at the screw-rod interface as well as within the rod
itself, a feature intended to lower the rate of screw loos-
ening. Biomechanical studies in cadavers have shown
that the device restores motion to the neutral zone even
after bilateral medial facetectomy. As with most systems,
it is pedicle screw based. In vitro studies have also shown
minimal effects of the adjacent segments. Clinical inves-
tigation of this device is under way. An FDA study was
started in 2007 aiming at terminating at the end of 2010,
but it has been terminated because the company has
ceased operation. Results were presented at the Spine
Arthroplasty Society (SAS) conference in 2010. With 12
to 24 months’ follow-up on 23 patients, there was sig-
nificant improvement postoperatively in comparison to
preoperatively and there were 4 occurrences of device/
screw failures.
There have been efforts such as the Percudyn system
(Interventional Spine, Irvine, California) consisting of a
pedicle anchor upon which sits a polycarbonate-urethane
stabilizer that serves as a mechanical stop between the
inferior and superior facets to stiffen the facet column. Its
bilateral fixation helps in stabilizing the spine in exten-
sion and lateral bending, and the bumper helps in off-
loading the facet joints by dissipating energy forces dor-
sally, reducing intradiscal pressure concomitantly. It is
undergoing clinical studies outside the United States, and
a 2-year follow-up study of 40 patients presented at the
SAS conference in 2009 shows satisfactory improvement
in pain.
In recent years the established companies have also
launched PEEK rod systems sometimes accompanied by
dynamic screws, such as the CD Horizon Legacy Peek Rod
System (Medtronic, Memphis, Tennessee) and Expedium
PEEK rod and Viper SC screw (DePuy Spine). Clinical
outcomes have yet to be reported to advocate these systems
for nonfusion treatments or topping-off long spinal fusion
constructs.
The future: The major challenges of current and future PDS
systems are to prevent implant and bone-implant interface
failures and to show efficacy. With modern metallurgy
techniques and bioengineering programs, devices will likely
be able to closely approximate, if not match, normal phys-
iologic motion and mechanics. However, this ability will be
short-lived if mechanical failure is inevitable. This can oc-
cur between the bone and the implant or within the implant
itself. More importantly, PDS systems must show efficacy
for the treatment of lumbar spine disorders. If they are used
as a post-laminectomy method of reconstruction, long-term
clinical benefit by preventing instability and ASD must be
shown. If they are to be used as a treatment for discogenic
low-back pain, they must show equivalent outcomes to
interbody fusion and/or TDR.
Facet replacement systems
The intervertebral disc is always considered as a source
of back pain. As degeneration of the disc advances, facet
load increases significantly,42 which ultimately leads to
facet arthrosis, which may in turn cause low-back pain.
Facet arthrosis is also a major contradiction for anterior disc
replacement.43 Facet replacements can permanently remove
the pain-generating articulation and capsule of the facet
joints. To address facet pain, stenosis, and disc degeneration
simultaneously, facet arthroplasty along with disc replace-
ment may be a viable treatment option. Such a combination
may restore motion and relieve patients from anterior, pos-
terior, and neurogenic pain.
The past:
Facet replacement patents appear as far back as the mid
1980s. However, it has not been until recently that devices
under this category have been brought to market. Early
proposed designs were primarily articular surface replace-
ments, similar to those for peripheral joint replacements.
Over time, designs have become larger and bulkier, replac-
ing not only the articular surfaces but the entire joint and its
supporting structures.
The present:
The current role of facet replacement is multifaceted. It
has been proposed as an adjunct to TDR, as a reconstruction
method after laminectomy, and as a treatment for facet-
mediated pain.
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One frequent contraindication for TDR is the presence of
facet arthritis.43 Continued motion across arthritic facet
joints is thought to be one of the causes of failed TDR
surgery. A reliable method of replacing the facet joint would
potentially avert this problem.
The so-called gold-standard reconstruction method after
a destabilizing laminectomy is lumbar fusion, which is
usually augmented with pedicle screws. Although this is a
successful procedure with excellent clinical outcomes, there
are a number of potential long-term drawbacks. ASD often
occurs above the fused segment, which can eventuate in
additional surgery.44 In addition, the immobilizing effects
of fusion do not restore the normal function and mechanics
of the decompressed segment, the ramifications of which are
not well understood. Facet replacement has been proposed
as an alternative to fusion and instrumentation after lami-
nectomy for spinal stenosis. Trials are currently under way
with a number of devices.
The facet replacement market segment is just now taking
shape. So far, Archus Orthopedics (Redmond, Washington)
has been a leader in the facet replacement market. One of
their devices, called the Total Facet Arthroplasty System
(TFAS), is a pedicle anchor–based system that relies on a
sliding ball-in-bowl–type joint (Fig. 8). It is a nonfusion
spinal implant indicated for treatment of patients with mod-
erate to severe spinal stenosis. TFAS replaces the diseased
facets (and lamina, if necessary to attain adequate decom-
pression) after surgical removal. TFAS offers an alternative
to rigid spinal fusion fixation enabling intervertebral motion
and restoration of stability and sagittal balance to the spine.
An IDE study was started in 2005 in which randomized
patients with lumbar stenosis were treated with either TFAS
stabilization or fusion with pedicle screws. The manufac-
turer underwent dissolution in 2009 and was acquired the
same year by Facet Solutions (Hopkinton, Massachusetts),
which was acquired by Globus Medical in early 2011. The
current status of the IDE recruitment status is unknown as
indicated on the National Institutes of Health FDA Clinical
Trials Web site.
Facet Solutions offers a device called the ACADIA Facet
Replacement System, also called the Anatomic Facet Re-
placement System (AFRS). It is also pedicle anchor based
but includes a metal-on-metal gliding joint that approxi-
mates the articular plane of the native facet joints. IDE
clinical trials were initiated in 2006, with an estimated study
completion date in 2013. In April 2009 the 1-year data for
the US Pilot Clinical Study were already published with
successful results showing improvements across all mea-
sures for lumbar stenosis treatment and no device-related
adverse events in any of the patients. The National Health
Service (NHS) and National Institutes of Health FDA clin-
ical trial Web site indicate that the IDE study is active,
although no verification updates were provided for 2011.
Impliant’s system (Princeton, New Jersey) is called the
TOPS system. Another pedicle screw–based design, it uses
an elastic core that is fixed to the anchors. By its design, the
Fig. 8. Total facet replacement devices: a, TFAS; b, ACADIA; and c, TOPS.
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TOPS system would more accurately be categorized as a
posterior dynamic fixation device because it functions pri-
marily as a flexible rod. There are not articulating surfaces
in the TOPS system. Patients are currently being enrolled in
an IDE clinical trial.
Spinal Elements (Carlsbad, California) has borrowed
technology from the hand arthroplasty market. Its design is
an interpositional resurfacing device that is affixed with a
locking bolt that traverses the articular processes. It is dis-
tinct from the other devices; it is an articular-surface re-
placement only, and it does not replace the facet joint and its
supporting structures. The TOPS has been in use since
2005, and an FDA trial started in 2006 with completion
expected in 2013.
Spinal Elements also offers the Zyre Facet Implant Sys-
tem; it is currently being trialed outside the United States,
and this began 2007. It consists of a spacer inserted within
the facet joint to augment its natural function while preserv-
ing the brunt of the facet joint bony structure.
The future:
In the future, facet replacement devices will require a
substantial amount of validation testing and numerous clin-
ical studies before they can be considered a viable treatment
option for the treatment of spinal disorders. To date, most
pathophysiologic research and thus surgical treatments have
been focused on the disc as a pain generator. A more
comprehensive focus on re-establishing the structure and
function of the human functional spinal unit may include
facet replacement. A better understanding of facet function
and facet-mediated pain, possibly through classification of
facet degeneration, may be needed to support the use of
such devices.
This approach can be illustrated somewhat by the Func-
tional Spinal Unit (FSU) Total Spinal Segment Replace-
ment device that has recently been released by Flexuspine
(Pittsburgh, Pennsylvania) (Fig. 9). The design aims to
replace the entire functional spinal unit by an interbody disc
component (a metal-on-metal cobalt-chromium core made
of articulating paired halves that are inserted through a
bilateral Transfacet Lumbar Interbody Fusion [TLIF] ap-
proach) and a posterior dynamic resistance component (a
sliding rod assembly with silicone dampeners fixed to the
spine with pedicle screws). In 2010 the FDA granted con-
ditional approval to begin the initial phase of an IDE study;
patient enrollment has yet to start to provide clinical out-
come feedback.
Conclusions
The development of a wide array of motion-preserving
devices heralds entrance into an era of partial and complete
functional spinal unit replacement. With this, a shift toward
using motion-sparing technology instead of fusion-type pro-
cedures will most likely take place in the near future. How-
ever, indications for these new technologies are still broad
and unproven and should be carefully considered and scru-
tinized, along with efforts to understand pain origins. Pro-
spective randomized clinical studies are essential to prove
the safety and efficacy of these technologies and to support
our quest to establish and practice evidence-based medicine.
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